Silco Pharmaceuticals Income Statement

Financials in millions BDT. Fiscal year is July - June.

Millions BDT. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	432.89	431.54	410.1	464.7	559.47	601.06
Revenue Growth (YoY)	5.56%	5.23%	-11.75%	-16.94%	-6.92%	-18.07%
Cost of Revenue	281.12	278.5	278.25	318.76	372.72	433.3
Gross Profit	151.78	153.04	131.85	145.93	186.75	167.76
Selling, General & Admin	64.81	64.82	62.74	69.74	80.98	80.09
Other Operating Expenses	-0	-0	-0	-0	-0	-0
Operating Expenses	74.77	74.78	72.68	78.75	89.27	88.37
Operating Income	77.01	78.26	59.17	67.18	97.48	79.39
Interest Expense	-0.58	-0.65	-0.93	-0.2	-0.53	-0.76
Interest & Investment Income	0.04	0.04	0.62	0.4	0.32	6.12
Other Non Operating Income (Expenses)	1.44	1.31	1.2	3.3	5.21	4.46
EBT Excluding Unusual Items	77.9	78.96	60.07	70.69	102.48	89.21
Gain (Loss) on Sale of Investments	-0.93	-0.93	-0.72	18.56	6.48	0.42
Pretax Income	76.97	78.03	59.35	89.24	108.96	89.63
Income Tax Expense	35.15	35.38	13.47	20.02	24.51	4.98
Net Income	41.83	42.65	45.88	69.22	84.45	84.65
Net Income to Common	41.83	42.65	45.88	69.22	84.45	84.65
Net Income Growth	-8.83%	-7.04%	-33.72%	-18.03%	-0.23%	1.77%
Shares Outstanding (Basic)	104	104	104	104	104	104
Shares Outstanding (Diluted)	104	104	104	104	104	104
Shares Change (YoY)	0.29%	-	-	-	-	-
EPS (Basic)	0.40	0.41	0.44	0.67	0.81	0.82
EPS (Diluted)	0.40	0.41	0.44	0.67	0.81	0.82
EPS Growth	-9.09%	-7.04%	-33.72%	-18.03%	-0.23%	1.77%
Free Cash Flow	14.87	7.54	0.05	-1.47	62.95	-119.22
Free Cash Flow Per Share	0.14	0.07	0.00	-0.01	0.61	-1.15
Dividend Per Share	-	0.110	0.100	0.300	0.500	1.000
Dividend Growth	-	10.00%	-66.67%	-40.00%	-50.00%	-
Gross Margin	35.06%	35.46%	32.15%	31.40%	33.38%	27.91%
Operating Margin	17.79%	18.14%	14.43%	14.46%	17.42%	13.21%
Profit Margin	9.66%	9.88%	11.19%	14.90%	15.10%	14.08%
Free Cash Flow Margin	3.43%	1.75%	0.01%	-0.32%	11.25%	-19.84%
EBITDA	166.14	167.29	147.77	153.9	172.16	153.98
EBITDA Margin	38.38%	38.77%	36.03%	33.12%	30.77%	25.62%
D&A For EBITDA	89.14	89.03	88.59	86.72	74.68	74.59
EBIT	77.01	78.26	59.17	67.18	97.48	79.39
EBIT Margin	17.79%	18.14%	14.43%	14.46%	17.42%	13.21%
Effective Tax Rate	45.66%	45.35%	22.70%	22.44%	22.49%	5.56%
Advertising Expenses	-	3.45	3.55	3.79	4.84	6.2

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.